Evidence map›Paper›PMID 30922256›Full record

SynthesisBMC cancer2019

Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies.

Liyun He, Huan Deng, Jun Lei, Fengming Yi, Jine Li, Xiu De Fan, Yiping Wei, Jianjun Xu, Wenxiong Zhang

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Targeted therapy for hepatocellular carcinoma.Signal transduction and targeted therapy · 2020
    Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Liyun HeDepartment of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, 1 Minde Rd, Nanchang, 330006, Jiangxi Province, China.
Huan DengDepartment of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, 1 Minde Rd, Nanchang, 330006, Jiangxi Province, China.
Jun LeiDepartment of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Fengming YiDepartment of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang, 330006, China.
Jine LiJiangxi Medical College, Nanchang University, Nanchang, 330006, China.
Xiu De FanDepartment of Infectious Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, China.
Yiping WeiDepartment of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, 1 Minde Rd, Nanchang, 330006, Jiangxi Province, China.
Jianjun XuDepartment of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, 1 Minde Rd, Nanchang, 330006, Jiangxi Province, China.
Wenxiong ZhangDepartment of Thoracic Surgery, The Second Affiliated Hospital of Nanchang University, 1 Minde Rd, Nanchang, 330006, Jiangxi Province, China. zwx123dr@126.com.ORCID http://orcid.org/0000-0003-2962-0847
Nanchang University · CNFirst Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

National Natural Science Foundation of Chin 81560345
6 · The paper itself

Abstract

backgroundThe efficacy of bevacizumab combined with erlotinib (B + E) for the treatment of advanced hepatocellular carcinoma, especially for sorafenib-refractory patients, has been observed and evaluated in several trials. We conducted this single arm meta-analysis to generally assess the benefit and risk with B + E for advanced hepatocellular carcinoma.

methodsThe PubMed, Cochrane Library, Embase, ScienceDirect, Web of Science and Scopus databases were searched for related studies. The main outcomes were objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS) and adverse effects (AEs).

resultsEight phase II clinical trials including 342 hepatocellular carcinoma patients were analyzed. The pooled ORR was 12.6% (95% CI: 6.3-19.0%), and the pooled DCR was 54.5% (95% CI: 48.9-66.8%). The 16-week PFS rate was 50.2% (95% CI: 38.2-62.2%). The 6- and 12-month OS rates were 77.8% (95% CI: 71.3-84.2%) and 44.9% (95% CI: 36.8-53.0%). The main grade 3-4 AEs were fatigue (11.9%), diarrhea (9.0%), hypertension (6.7%), acne (5.8%) and hemorrhage (5.3%). The only RCT showed that the B + E regimen had a consistent response and equable median OS but fewer toxicities (grade 3-4 AEs: 19% vs. 27%) than sorafenib. Subgroup analysis showed that as a second-line treatment, the B + E regimen had substantial value with a favorable PFS-16w (P = 0.012), OS-12 m (P = 0.048) and a favorable tendency of ORR (P = 0.089), but obvious toxicities in the second-line setting could not be neglected.

conclusionBevacizumab combined with erlotinib is effective for treating hepatocellular carcinoma patients, especially sorafenib-refractory patients. More well-designed and large-scale RCTs are warranted to prove our findings.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, HepatocellularClinical Trials, Phase II as TopicErlotinib HydrochlorideFemaleHumansLiver NeoplasmsMaleMiddle AgedProspective StudiesSurvival AnalysisTreatment OutcomeBevacizumabErlotinib HydrochlorideBevacizumabErlotinibHepatocellular carcinomaMeta-analysisSorafenib

Identifiers

PMID30922256
PMCPMC6437948
OpenAlexW2939243934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.